Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Laboratory-treated T cells may be able to kill tumor cells when they are put back
into the body. Aldesleukin and cyclophosphamide may stimulate the immune system in different
ways and stop tumor cells from growing. Giving laboratory-treated T cells together with
aldesleukin after cyclophosphamide may be an effective treatment for melanoma.
PURPOSE: This phase I/II trial is studying the side effects of giving laboratory-treated T
cells together with aldesleukin after cyclophosphamide and to see how well they work in
treating patients with stage IV melanoma.